Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for the diagnosis, prognosis and treatment of prostate cancer metastasis

a prostate cancer and metastasis technology, applied in the field of prostate cancer metastasis diagnosis, prognosis and treatment, can solve the problems of slow growth of most prostate cancers, difficulty in urination, problems during sexual intercourse, erectile dysfunction, etc., and achieve the effect of preventing or reducing the risk of bone metastasis

Inactive Publication Date: 2014-04-17
INBIOMOTION
View PDF1 Cites 29 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent describes a method for preventing or reducing the risk of bone metastasis in patients with prostate cancer. This method involves administering an agent that prevents bone metastasis to patients based on a treatment regimen determined by measuring the level of a specific protein called c-MAF.

Problems solved by technology

Most prostate cancers are slow growing; however, there are cases of aggressive prostate cancers.
Prostate cancer may cause pain, difficulty in urinating, problems during sexual intercourse, or erectile dysfunction.
Moreover, prostate test screening is controversial at the moment and may lead to unnecessary, even harmful, consequences in some patients.
Not only is this test quick, it is also sensitive.
Such screening is controversial and, in some patients, may lead to unnecessary, even harmful, consequences.
This USPSTF recommendation, released in October 2011, is based on “review of evidence” studies concluding that “Prostate-specific antigen-based screening results in small or no reduction in prostate cancer-specific mortality and is associated with harms related to subsequent evaluation and treatments, some of which may be unnecessary.
Once trapped, cancerous cells can begin their cycle of unhealthy division and result in lymph node metastasis.
However, it is unknown whether the developmental history of a cancer would result in different or common mediators of site-specific metastasis.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
  • Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
  • Method for the diagnosis, prognosis and treatment of prostate cancer metastasis

Examples

Experimental program
Comparison scheme
Effect test

example 1

c-MAF Expression is Associated with Risk of Metastasis, in Particular Bone Metastasis

Immunohistochemistry Analysis

[0345]c-MAF immunostaining was performed on TMAs. This TMA was build on glass slides and IHC was done using the Dako Link Platform according the Operating Procedure

[0346]Briefly, the immunostaining was done on 3 μm TMA tumor tissue sections, placed on positively charged glass slides (Superfrost or similar) in a Dako Link platform. After deparaffinization, heat antigen retrieval was performed in pH 6.1, 0.01 mol / L citrate-based buffered solution (Dako). Endogenous peroxidase was quenched. The mouse polyclonal anti-c-MAF antibody (Santa Cruz) 1:100 dilution was used for 30 minutes at room temperature, followed by incubation with an anti-rabbit Ig dextran polymer coupled with peroxidase (Flex+, Dako). Sections were then visualized with 3,3′-diaminobenzidine (DAB) and counterstained with Hematoxylin.

[0347]c-MAF immunostaining was scored by a computerized algorithm. Nine repr...

example 2

Gain of 16q22-24 Chromosomal Region (CNA, Copy Number Alteration) is Associated with Risk of Bone Metastasis

[0355]We tested whether a gain in chr16q22-q24, which included c-MAF genomic loci, is associated with risk of bone metastasis in Prostate cancer patients. To this end we used a method that identifies chr16q22-q24 amplifications, in this case by means of a chr16q23 and chr14q32 dual fluorescence in situ hybridization (FISH) probe to measure the number of copies of the chr16q22-24 region. We also used the chr14q32 probe to normalize tumor polyploidy.

[0356]Fluorescent in situ hybridization (FISH) analysis of 16q23, within the 16q22-24, genomic region amplification, including the c-MAF gene, was performed on TMA above described using a fluorescence DM2000 Leica microscope according to the Operating Procedure. We used a SpectrumOrange probe mix that flanks the MAF gene genomic region and is composed of two segments that are each approximately 350 kb with an approximately 2.2 Mb gap...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a method for the diagnosis or the prognosis of metastasis in prostate cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in prostate cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the prostate cancer.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims priority under 35 U.S.C. §119(e) to U.S. Provisional Patent Application Ser. No. 61 / 713,318, filed on Oct. 12, 2012, and incorporated herein by reference in its entirety.REFERENCE TO SEQUENCE LISTING[0002]The content of the electronically submitted sequence listing (“3190—0030001 SEQIDListing_ascii.txt”, 48,245 bytes, created on Oct. 7, 2013) filed with the application is incorporated herein by reference in its entirety.BACKGROUND OF THE INVENTION[0003]1. Field of the Invention[0004]The present invention relates to the diagnosis or the prognosis of metastasis in prostate cancer based on determining if the c-MAF gene, within the 16q22-24 genomic region, is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in prostate cancer, as well as to a method for designing a customized therapy in a subject with prostate cancer, which comprises ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/68
CPCC12Q1/6886C12Q2600/118C12Q2600/158G01N2333/82G01N2800/56G01N33/57434A61K31/47A61K31/675A61P19/00A61P19/08A61P35/00A61P35/04C12Q2600/112C07K16/18C07K2317/21C07K2317/569G01N2800/52
Inventor GOMIS, ROGERJEAN-MAIRET, JO L
Owner INBIOMOTION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com